Artelo Biosciences Inc (ARTL) — Cash Flow-to-Debt Ratio
Artelo Biosciences Inc (ARTL) has a Cash Flow-to-Debt Ratio of -1.04x as of December 2025, meaning its operating cash flow of $-4.25 Million could theoretically repay -1% of its total liabilities ($4.07 Million) in one year. Explore ARTL long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Artelo Biosciences Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Artelo Biosciences Inc across 11 annual periods. Also explore ARTL total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Artelo Biosciences Inc (2015–2025)
Year-by-year debt coverage analysis for Artelo Biosciences Inc. For market capitalisation and broader financial context, see ARTL market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.09x | $-8.52 Million | $4.07 Million | ▲ +53.9% |
| 2024 | -4.54x | $-8.35 Million | $1.84 Million | ▲ +28.7% |
| 2023 | -6.36x | $-8.21 Million | $1.29 Million | ▲ +18.9% |
| 2022 | -7.84x | $-8.01 Million | $1.02 Million | ▲ +24.3% |
| 2021 | -10.36x | $-6.14 Million | $593.00K | ▼ -19.6% |
| 2020 | -8.66x | $-4.35 Million | $502.18K | ▼ -216.7% |
| 2019 | -2.73x | $-2.79 Million | $1.02 Million | ▲ +9.7% |
| 2018 | -3.03x | $-1.61 Million | $531.97K | ▲ +58.9% |
| 2017 | -7.37x | $-216.82K | $29.44K | ▼ -592.8% |
| 2016 | -1.06x | $-18.49K | $17.39K | ▲ +86.3% |
| 2015 | -7.76x | $-13.50K | $1.74K | — |